CD40LG and infection: IgM recognizing cross-reactive EDIII epitopes averaged 37% and 55% in primary and secondary infections respectively, whereas EDIII cross-reactive IgG averaged only 7.5% and 4% of primary and secondary DENV-2 infected patient sera (Table 6).